← Leaderboards
Liqiang Chen
University Of Minnesota
$850,625
Attributed
$850,625
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $232.5K · FY2020–23$250K$187.5K$125K$62.5K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$850,625 · 2
By mechanism
R21$850,625 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota
Same institution · by research overlap
- Zhengqiang Wang$10,211,439
- Fang Li$9,155,528
- Hideki Aihara$15,628,976
- Richard F Maclehose$1,987,122
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoMethylationEffective TherapyIn VitroLead OptimizationMetabolismDrug KineticsAbsorptionExcretory FunctionInnovationIsoenzymesBinding SitesBiochemicalBiological AvailabilityAnimal ModelDesignCombatComputer ModelsAntiviral AgentsEnzymesAqueousFutureAnalogMethyltransferase
Grant awards (4)
Bi-substrate Inhibitors of SARS-CoV-2 Nsp14 Methyltransferase$232,500
R21 · FY2023 · AI · contact PI
Bi-substrate Inhibitors of SARS-CoV-2 Nsp14 Methyltransferase$193,750
R21 · FY2022 · AI · contact PI
Optimizing Zika NS5 Methyltransferase Inhibitors$231,875
R21 · FY2021 · AI · contact PI
Optimizing Zika NS5 Methyltransferase Inhibitors$192,500
R21 · FY2020 · AI · contact PI